Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.

Japanese journal of pharmacology Pub Date : 2002-03-01 DOI:10.1254/JJP.88.300

T. Matsuo, E. Ishikawa, M. Ohta, Y. Shibouta, Y. Ishimura, Y. Imura, Y. Sugiyama

{"title":"Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.","authors":"T. Matsuo, E. Ishikawa, M. Ohta, Y. Shibouta, Y. Ishimura, Y. Imura, Y. Sugiyama","doi":"10.1254/JJP.88.300","DOIUrl":null,"url":null,"abstract":"Spontaneously hypercholesterolemic (SHC) rats exhibit hypercholesterolemia, proteinuria and focal glomerulosclerosis with age, and they finally die as a result of renal failure. In this study, the renoprotective effects of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, and enalapril, an angiotensin I converting enzyme inhibitor, were examined in SHC rats. Candesartan cilexetil (0.1 and 1 mg /kg) and enalapril (10 mg/kg) were administered orally to 10-week-old SHC rats for a 6-week period. Candesartan cilexetil (1 mg/kg) and enalapril (10 mg/kg) significantly inhibited proteinuria and hypercholesterolemia to a similar extent. In untreated 16-week-old SHC rats, glomerulosclerosis, basophilic change, cast formation and interstitial mononuclear cell infiltration were observed. Candesartan cilexetil (1 mg/kg) inhibited all of these histological changes. Enalapril inhibited glomerulosclerosis and cast formation. These results show that candesartan cilexetil and enalapril have renal protective effects in SHC rats. Thus, angiotensin II might play an important role in renal pathogenesis in a model of focal glomerulosclerosis with hypercholesterolemia.","PeriodicalId":14750,"journal":{"name":"Japanese journal of pharmacology","volume":"71 1","pages":"300-6"},"PeriodicalIF":0.0000,"publicationDate":"2002-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1254/JJP.88.300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

Spontaneously hypercholesterolemic (SHC) rats exhibit hypercholesterolemia, proteinuria and focal glomerulosclerosis with age, and they finally die as a result of renal failure. In this study, the renoprotective effects of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, and enalapril, an angiotensin I converting enzyme inhibitor, were examined in SHC rats. Candesartan cilexetil (0.1 and 1 mg /kg) and enalapril (10 mg/kg) were administered orally to 10-week-old SHC rats for a 6-week period. Candesartan cilexetil (1 mg/kg) and enalapril (10 mg/kg) significantly inhibited proteinuria and hypercholesterolemia to a similar extent. In untreated 16-week-old SHC rats, glomerulosclerosis, basophilic change, cast formation and interstitial mononuclear cell infiltration were observed. Candesartan cilexetil (1 mg/kg) inhibited all of these histological changes. Enalapril inhibited glomerulosclerosis and cast formation. These results show that candesartan cilexetil and enalapril have renal protective effects in SHC rats. Thus, angiotensin II might play an important role in renal pathogenesis in a model of focal glomerulosclerosis with hypercholesterolemia.

查看原文本刊更多论文

坎地沙坦西莱地酯对自发性高胆固醇血症大鼠肾脏的保护作用。

自发性高胆固醇血症(SHC)大鼠随着年龄的增长表现为高胆固醇血症、蛋白尿和局灶性肾小球硬化，最终因肾功能衰竭而死亡。在本研究中，研究了血管紧张素II型1受体拮抗剂坎地沙坦西列地酯和血管紧张素I转换酶抑制剂依那普利对SHC大鼠的肾保护作用。给10周龄SHC大鼠口服坎地沙坦西列地酯(0.1和1 mg/kg)和依那普利(10 mg/kg)，为期6周。坎地沙坦西列地酯(1mg /kg)和依那普利(10mg /kg)显著抑制蛋白尿和高胆固醇血症的程度相似。未经治疗的16周龄SHC大鼠肾小球硬化、嗜碱性改变、铸型形成和间质单核细胞浸润。坎地沙坦西莱西酯(1mg /kg)抑制了所有这些组织学变化。依那普利抑制肾小球硬化和铸型形成。结果表明坎地沙坦西列地酯和依那普利对SHC大鼠具有肾脏保护作用。因此，血管紧张素II可能在局灶性肾小球硬化伴高胆固醇血症模型的肾脏发病机制中起重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese journal of pharmacology

自引率

0.00%

发文量